GlassScriptPhysician profile
Jordan S Orange
NPI 1033123591
$203,385.57
in general payments reported to CMS, 2019-2025
11 companies · $616 in 2025
The $616 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $19K · 2021: $32K · 2022: $24K · 2023: $31K · 2024: $47K · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Travel and Lodging: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,375 · Food and Beverage: $828 · Education: $59.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $59,887.50 |
| Travel and Lodging | $13,502.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,375.00 |
| Food and Beverage | $828.23 |
| Education | $59.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $56,192.12 | 2020-2025 | Cuvitru, Gammagard Liquid |
| Grifols USA, LLC | $50,061.10 | 2020-2024 | Xembify |
| Shire North American Group INC | $42,164.30 | 2019 | |
| Csl Behring | $22,144.63 | 2022-2023 | Hizentra |
| Adma Biomanufacturing LLC | $15,000.00 | 2019-2020 | |
| Sobi, INC | $6,120.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $5,240.00 | 2021 | |
| Grifols, S.A. | $4,375.00 | 2023 | |
| Janssen Research & Development, LLC | $1,890.00 | 2021 | |
| Horizon Therapeutics Plc | $118.39 | 2020 | |
| Medtronic, INC. | $80.03 | 2025 | Invos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Orange listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.